Letter to the Editor
Treatment of children from 6 to 11 years old affected by moderate–severe atopic dermatitis with dupilumab: a first perspective from a single-center real-life experience in Italy
No abstract is available for this article.
Conflicts of interest
The authors have no conflicts of interest to disclose.
Open Research
Data availability statement
Data available on request due to privacy/ethical restrictions.
